VDC vs XBI
Vanguard Consumer Staples ETF vs SPDR S&P Biotech ETF
- • VDC has the lower expense ratio at 0.09% vs 0.35% for XBI.
- • VDC pays a higher dividend yield (2.08%).
Side-by-side metrics
| Metric | VDC | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.09% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.08% | 0.34% |
AUM Assets under management — bigger funds are typically more liquid. | $9.54B | $8.30B |
YTD return | 9.76% | 12.92% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.63 | 1.09 |
P/E ratio | 26.30 | — |
Last price | $229.94 | $133.66 |
Inception | — | — |
Issuer | Vanguard | State Street |
VDC top holdings
| WMT | Walmart Inc | 15.71% |
| COST | Costco Wholesale Corp | 12.44% |
| PG | Procter & Gamble Co | 9.25% |
| KO | Coca-Cola Co | 8.32% |
| PEP | PepsiCo Inc | 4.59% |
| PM | Philip Morris International Inc | 4.31% |
| MO | Altria Group Inc | 3.68% |
| MDLZ | Mondelez International Inc Class A | 2.51% |
| CL | Colgate-Palmolive Co | 2.22% |
| TGT | Target Corp | 1.92% |
XBI top holdings
| APLS | Apellis Pharmaceuticals Inc | 1.87% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.65% |
| TVTX | Travere Therapeutics Inc Ordinary Shares | 1.62% |
| ARWR | Arrowhead Pharmaceuticals Inc | 1.44% |
| TWST | Twist Bioscience Corp | 1.42% |
| SMMT | Summit Therapeutics Inc Ordinary Shares | 1.40% |
| ALKS | Alkermes PLC | 1.38% |
| TGTX | TG Therapeutics Inc | 1.37% |
| MDGL | Madrigal Pharmaceuticals Inc | 1.36% |
| BEAM | Beam Therapeutics Inc | 1.32% |
About VDC
VDC (Vanguard Consumer Staples ETF) is US consumer staples sector stocks. Managed by Vanguard, the fund carries $9.5B in assets under management, an expense ratio of 0.09%, a dividend yield of 2.08%. Its largest holding is Walmart Inc (WMT), which represents 15.7% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 1.6%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $8.3B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.34%. Its largest holding is Apellis Pharmaceuticals Inc (APLS), which represents 1.9% of the portfolio. Financial Services is the fund's largest sector exposure at 0.2%.